Minerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016
November 10 2016 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will present at the Jefferies 2016 London Healthcare
Conference on November 17, 2016 at 12:40 p.m. GMT (7:40 a.m. EST).
The presentation will be web cast and accessible through the
investor relations section of the Company’s web site,
http://ir.minervaneurosciences.com.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
which has completed a Phase IIb clinical trial for schizophrenia;
MIN-117, which has completed a Phase IIa clinical trial development
for MDD; MIN-202 (JNJ-42847922), which has completed Phase
IIa and Phase Ib clinical trials for insomnia and MDD,
respectively; and MIN-301, in pre-clinical development for
Parkinson’s disease. Minerva’s common stock is listed on the
NASDAQ Global Market under the symbol “NERV.” For more
information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024